Starbucks rolls back weight-loss drug coverage as costs surge

The decision reflects a growing trend among large employers struggling with the financial burden of high-demand obesity treatments. While these drugs were originally formulated for diabetes management, their widespread adoption for weight loss has placed immense pressure on corporate healthcare funds. According to data from the International Foundation of Employee Benefit Plans, GLP-1 claims jumped to 11.4% of total annual corporate spending last year, up from 6.9% in 2023.

Mercer reports that average health-benefit costs per employee are projected to climb 6.7% this year, with expensive weight-loss medications identified as a primary driver. This fiscal reality has led other major organizations, such as Allina Health and PwC, to terminate similar coverage. Conversely, some firms maintain their commitment to these treatments; Bank of America CEO Brian Moynihan recently confirmed the bank allocates over $250 million annually to GLP-1 coverage, classifying the expense as a strategic investment in the long-term health of its workforce.